|
KMID : 1200020160400050339
|
|
Diabetes & Metabolism Journal
2016 Volume.40 No. 5 p.339 ~ p.353
|
|
|
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
|
|
Kim Sung-Ho
Yoo Jung-Hwa
Lee Woo-Je
Park Cheol-Young
|
|
|
Abstract
|
|
|
|
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing postprandial hyperglycemia. Although DPP-4 inhibitors have similar benefits, they can be differentiated in terms of their chemical structure, pharmacology, efficacy and safety profiles, and clinical considerations. Gemigliptin (brand name: Zemiglo), developed by LG Life Sciences, is a potent, selective, competitive, and long acting DPP-4 inhibitor. Various studies have shown that gemigliptin is an optimized DPP-4 inhibitor in terms of efficacy, safety, and patient compliance for treatment of type 2 diabetes mellitus. In this review, we summarize the characteristics of gemigliptin and discuss its potential benefits in clinical practice.
|
|
|
KEYWORD
|
|
|
Diabetes mellitus, type 2, Dipeptidyl-peptidase IV inhibitors, LC15-0444
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|
|